NCT05345158View on ClinicalTrials.gov

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

NARecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Lymphadenopathy RetroperitonealStage II Testicular Seminoma
Interventions
PROCEDURE

Robotic Retroperitoneal Lymph Node Dissection (RPLND)

Robotic RPLND performed using the DaVinci robotic surgical system.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER